SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: CoinOp, saj, beambe, l2 hunter, Jp111, MANOLO1775
Search This Board:
Last Post: 1/20/2017 10:58:16 PM - Followers: 86 - Board type: Free - Posts Today: 0


Nasdaq"NVCN" AND

US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement
12/2/2016 7:00:00 AM - PR Newswire

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
12/2/2016 7:00:00 AM - PR Newswire

MAJOR HOLDER OWNERSHIP ALSO RISES NOW TO 58 MILLION SHARES Direct Holders own 32mil ,Institutions 16mil,Mutual Funds 10mil , with new $BSX stake now added to Direct Holders


Latest Analyst Ratings:

Leerink Reaffirms Neovasc (NVCN) at 'Outperform' Amid Boston Scientific Deal

December 2, 2016 11:57 AM 

Leerink affirms Neovasc Inc. (Nasdaq: NVCN) at Outperform with a price target of $10 following news of an asset sales agreement with Boston Scientific (NYSE: BSX)


Neovasc's Tiara and other TMVR devices




                                                                                   Nasdaq: NVCN

                                                                                      Contact Info
13562 Maycrest Way #5138, Richmond,

                                                                                  BC V6V 2j7 Canada
                                                                            Fax: 1.604.270.4384
                                                                            Email: [email protected]

                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 


Neovasc Tiara

Tiara is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.

Neovasc is developing the Tiara for the treatment of severe MR, a condition that affects approximately four million patients in the U.S. alone. Currently, conventional surgical treatments are only appropriate for about 20% of these patients, leaving the majority of patients untreated.

The Tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart.

Tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve, rather than being adapted from an aortic valve. Tiara implantation is achieved through a transapical approach and does not require any hemodynamic support.


Neovasc Reducer

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.



Opko Investee Neovasc $9B Massive and Virtually Unpenetrated Market Opportunity

                                   ****   Leerink Partners Starts Neovasc (NVCN) at Outperform, $15 PT ****,+$15+PT/10390409.html

                                          Successfully increasing financing year to year through Institutional Public Offerings
                              sets a tone to a growing Value in its Marketplace.

                                                               6-k dated May 2014 

"For the three months ended March 31, 2014, net cash provided by financing activities was $24,658,642 compared to $194,010 for the same period in 2013. On March 26, 2014, the Company closed a bought deal equity financing underwritten by Cormark Securities Inc., which placed 4,192,000 common shares of Neovasc at a price of $6.00 per common share, for gross cash proceeds to the Company of $25,152,000. The share issue cost was $506,651." 

                                                                6-k dated May 2015 

"For the three months ended March 31, 2015, net cash provided by financing activities was $88,143,429, compared to $24,658,642 for the same period in 2014. On February 3, 2015, the Company closed an underwritten public offering of 12,075,000 common shares of the Company (of which 10,415,000 common shares were issued from treasury and 1,660,000 common shares were sold by certain directors, officers and employees of the Company) at a price per share of US$7.19 for aggregate gross proceeds of approximately US$74,883,850 for the Company and US$11,935,400 for the selling security holders. The share issue costs incurred by the Company were $6,236,783. "

**NEWEST UPDATED INFO  6/15/16 - 6-K FILING SHOWS 81.28% Longs/Institutional Ownership from voting results**
(the “Company”)
Annual General Meeting of Shareholders
June 15, 2016
(Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations )
Common Shares represented at the Meeting:
Total issued and outstanding Common Shares as at Record Date:
Percentage of issued and outstanding Common Shares represented:


 May 4 ,2016 6-k filing here has  #1 holder with 22.1% " Dr. Phillip Frost" of Frost Gamma Investments Trust  
Shareholder Name   Number of Shares Held     Percentage of Issued Shares  
Frost Gamma Investments Trust      14,786,219       22.1 %


******Major Ownership Here: Funds & Institutions & Direct

Holders @Barrons has over

50+ Million Shares Owned !!! *****

****{ Major amount of this was purchased at the $6.00 & $7.19 level!! }

Latest Update here***********
As at November 14, 2016, the Company had 66,866,345 common voting shares issued and outstanding

Outstanding Share Data 
August 9, 2016, the Company had 66,866,345 common voting shares issued and outstanding
"Remaining Non Dilutive to Shareholders as Direct Funding has been their proven successful funding arena"

August 6, 2015, the Company had 66,551,447 common shares issued and outstanding
August 12, 2014, the Company had 53,756,932 common voting shares issued and outstanding


Most recent broker ratings

05/20/2016 – Neovasc Inc. was downgraded to “neutral” by analysts at Ladenburg Thalmann.

03/30/2016 – Neovasc Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 9.5 price target on the stock.

10/07/2015 – JMP Securities began new coverage on Neovasc Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock.

09/23/2015 – Neovasc Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

03/31/2015 – Northland Securities began new coverage on Neovasc Inc. giving the company a “outperform” rating. They now have a USD 12 price target on the stock.


                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"



  Neovasc the small cap medical device company has a promising set of catalysts approaching for its core tissue division and for its two life saving vascular devices, The Reducer and The Tiara. The Reducer recently released extremely positive top line results of its sham-controlled COSIRA trial, and full results should be released by the end of the month. The device is already CE marked in Europe, and is the first minimally invasive treatment for Refractory Angina. Based off of comparable devices, the device can be worth anywhere from $5.00 to $14.00 per share.

The Tiara has received an extremely broad patent for treating Mitral Regurgitation, and is the frontrunner in bringing an effective product to the market for the first time ever. Neovasc tested the device in animals and recently published strong data supporting the safety and efficacy of the device. The first human implantation is scheduled for Q1 of 2014. If approved and brought to market, this would be a billion dollar device.

Neovasc's Peripatch tissue division continues to boast strong growth and profit numbers, as shown in its latest quarterly filing. This profitable division should see increased revenues as more of Neovasc's customers gain FDA approval for their vascular devices that utilize Neovasc's Peripatch tissue. The profit generated from the tissue division funds the development of The Reducer and The Tiara, which is unique for a small medical company, which would usually have to rely on secondary offerings (dilution) to generate the necessary development funds. The expanding growth of Neovasc and its tissue division will not end anytime soon as they finalize the divestment of its low margin patch division and benefit from the rapidly growing heart valve market.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVCN News: Report of Foreign Issuer (6-k) 01/18/2017 03:33:44 PM
NVCN News: Neovasc Announces Update in Litigation with CardiAQ 01/18/2017 02:04:00 PM
NVCN News: Neovasc Announces Update in Litigation with CardiAQ 01/18/2017 02:04:00 PM
NVCN News: Report of Foreign Issuer (6-k) 12/28/2016 07:19:26 AM
NVCN News: Neovasc Announces Update in Litigation with CardiAQ 12/23/2016 12:28:00 PM
#2892  Sticky Note NVCN $10 TARGET AFTER MERGER NEWS >>> Leerink l2 hunter 12/05/16 08:35:45 AM
#1877  Sticky Note "Recent deals involving mitral valve companies" CoinOp 10/25/16 12:46:24 AM
#1857  Sticky Note NVCN $0.52 only 16m float / 66m O/S. l2 hunter 10/19/16 03:22:07 AM
#4005   Ouch..rough week. One of these days it will RunningRiot 01/20/17 10:58:16 PM
#4004   I sold and went to AMFE thats a INFINITI 01/20/17 11:24:38 AM
#4003   Yeah it might but not anytime soon need INFINITI 01/20/17 11:23:50 AM
#4002   Really? How about when NVCN goes over $4+, ttmasher 01/20/17 11:14:37 AM
#4001   Slowly going down smh INFINITI 01/20/17 09:37:54 AM
#4000   Wow thk god i sold couple days ago INFINITI 01/19/17 11:44:00 AM
#3999   Neovasc on the hook for hefty interest in Pittkid 01/18/17 03:45:32 PM
#3998   Red, red, red, and more red. This is RunningRiot 01/18/17 02:40:22 PM
#3997   I am not much of a loler when RunningRiot 01/18/17 02:21:58 PM
#3996   Lol Hana3 01/18/17 02:20:20 PM
#3995   I don't see this going north anytime soon. RunningRiot 01/18/17 02:19:46 PM
#3994   Well that isn't very optimistic news RunningRiot 01/18/17 02:17:23 PM
#3993   Waiting for turn north Hana3 01/18/17 01:06:09 PM
#3992   Really? No volume, cannot get over 200th in ttmasher 01/17/17 12:15:05 PM
#3991   Zzzzzzzzzz RunningRiot 01/17/17 10:16:39 AM
#3990   Priming for complete takeover with 15% stake , CoinOp 01/17/17 03:49:07 AM
#3989   It will jump soon.... 1syndicate 01/15/17 02:01:47 PM
#3988   Short squeeze info newest recent update up now CoinOp 01/15/17 01:06:35 AM
#3987   CMF indicator went positive on Thursday and Friday CoinOp 01/15/17 12:51:47 AM
#3986   Maybe no rush, but should be above $3? ttmasher 01/14/17 08:45:25 AM
#3985   They are gearing up for a great 1syndicate 01/13/17 06:43:40 PM
#3984   All in this morning, hope for the Hana3 01/13/17 09:52:18 AM
#3983   Boston got a great deal at .60, no ttmasher 01/13/17 09:13:22 AM
#3982   I do no think a buyout is likely.....unless 1syndicate 01/12/17 02:10:01 AM
#3981   A buyout from Boston Scientific could be actually CoinOp 01/11/17 11:47:45 PM
#3980   4-6 weeks, maybe sooner. I anticipate a run Louman 01/11/17 05:56:31 PM
#3979   A buyout is unlikely with big brother Boston 1syndicate 01/11/17 02:22:20 PM
#3978   Already in, but NVCN needs to get past ttmasher 01/11/17 11:10:15 AM
#3977   NVCN will run up at some point and 1syndicate 01/11/17 11:01:43 AM
#3976   You could be right! But for now cannot ttmasher 01/11/17 09:51:25 AM
#3975   Good luck Hana.....this is going to be fun.....$$$$$$ 1syndicate 01/10/17 10:56:05 PM
#3974   Good , money is clear now . Scottrade. Hana3 01/10/17 07:51:24 PM
#3973   All in and just relaxing......2017 will a great 1syndicate 01/10/17 07:40:13 PM
#3972   No, I'm holding for the etrm kind of run. RunningRiot 01/10/17 04:04:15 PM
#3971   So quiet here , everyone out ? Hana3 01/10/17 02:06:47 PM
#3970   Nice INFINITI 01/10/17 09:40:03 AM
#3969   Moving up nice breaking 2.05 will be good 10bags 01/09/17 02:56:43 PM
#3968   Nice INFINITI 01/09/17 01:02:15 PM
#3967   I think you should get in now and tdot555 01/08/17 01:47:55 AM
#3966   Opinions on a good entry price for this Vill50 01/07/17 11:04:03 PM
#3965   $6+ then $10+ to uncharted territory for NVCN CoinOp 01/07/17 01:38:58 AM
#3964   True, NVCN has stalled! Soon NVCN will get ttmasher 01/05/17 11:34:09 AM
#3963   Bummer INFINITI 01/05/17 08:57:23 AM
#3962   Next milestone of growth coming and money CoinOp 01/04/17 04:03:09 AM
#3961   Come one look at all these runners on RunningRiot 01/03/17 10:54:04 AM
#3960   Yeah it isn't moving that's for sure. But RunningRiot 01/03/17 10:25:22 AM
#3959   Same oh shiat here blah blah blah INFINITI 01/03/17 09:31:25 AM
#3958   Gl need to make money elsewhere if this INFINITI 12/31/16 01:15:11 PM
#3957   Lol not me..holding core until 8 bucks or .0001 RunningRiot 12/31/16 01:14:04 PM
#3956   Im out gl everyone patience lost INFINITI 12/31/16 10:42:43 AM